You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The test can be used directly on any open instrument, including portable systems, and it allows for detection of pathogens in about 75 minutes.
Eurobio Scientific will also develop new test kits for the T-COR 8, a real-time PCR thermocycler originally developed for the US Army.
Panasonic of Osaka, Japan, has received US Patent Nos.
NEW YORK (GenomeWeb News) – French biotech firm Exonhit announced today an agreement to acquire InGen BioSciences for €18 million ($23.1 million), forming a new firm called Diaxonhit.
NEW YORK (GenomeWeb News) – Exonhit today said it has been awarded €1.9 million ($2.4 million) to participate in a project aimed at developing new treatments for cancers and tools to identify patients who may be best candidates for the treatments.
An institutional review board has approved a pilot clinical trial aimed at evaluating the performance of ExonHit Therapeutics' test for Alzheimer's disease, AclarusDx.
NEW YORK (GenomeWeb News) – Exonhit today announced a deal with Pfizer for use of Exonhit's technology for identifying biomarkers associated with Alzheimer's disease.
Officials from both organizations said this week that they are keen to use Exonhit's SpliceArray platform in new, sequencing-driven biomarker discovery projects.
The project combines BGI's next-generation sequencing and Exonhit's SpliceArray technologies to expand the SpliceArray platform to an additional "strategic preclinical animal model species."
The World Health Organization will be providing low-cost COVID-19 tests to low- and middle-income nations, according to Reuters.
Nature News examines how the confirmation of Amy Coney Barrett to the US Supreme Court could affect scientific agencies.
Nobel Prize-winner Arthur Ashkin, who developed optical tweezers, has died at 98, the Washington Post reports.
In PNAS this week: altered gene expression in brain samples from Alzheimer's disease patients, effects of gene mutations found in bladder cancer, and more.